Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

89.06 -2.37 (-2.59%)
Streaming Delayed Price Updated: 1:08 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults
The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains of bacteria. Additionally, Merck's Keytruda received FDA approval for advanced... 
Via Benzinga
Exposures Product Safety
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
From Merck & Co., Inc.
Via Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck & Co Unusual Options Activity For June 14
Via Benzinga
How Is The Market Feeling About Merck & Co?
Via Benzinga
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
Exposures COVID-19
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
These high-flying stocks could have more room to run if analysts are right. 
Via The Motley Fool
3 Crazy Good Stocks to Buy With $500 Right Now
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential. 
Via InvestorPlace
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Comparative Study: Merck &amp; Co And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Smart Money Is Betting Big In MRK Options
Via Benzinga
3 High-Yield Dividend Stocks to Collect Impressive Payouts Year After Year
High-yield dividend stocks can be resilient performers in long-term portfolios and provide steady income and robust growth in June. 
Via InvestorPlace
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. 
Via Talk Markets
From $10k to $100k: 3 Stocks With the Potential for Amazing Returns
Generate massive returns on investment with these three stocks to buy that have the potential to become market beaters in 2024 and beyond. 
Via InvestorPlace
Nike, Merck, General Motors, And More: CNBC's 'Final Trades'
Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of Cerity Partners picks General Motors, while Jason Snipe of Odyssey Capital... 
Via Benzinga
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
Exposures COVID-19
Why Moderna Stock Is a No-Brainer Buy Right Now
This messenger-RNA pioneer should be able to keep its rebound going. 
Via The Motley Fool
3 Reasons to Buy Moderna Stock
The biotech hasn't said its last word. 
Via The Motley Fool
2 Dividend Stocks Billionaires Are Buying: Should You?
That's not a bad crowd to follow when investing in stocks. 
Via The Motley Fool
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside 
Via InvestorPlace
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial.  On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... 
Via Benzinga
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3... 
Via Benzinga
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
Via ACCESSWIRE
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
Via Talk Markets
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly... 
Via Benzinga
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
Surmodics stock hit a two-year high on its GPCR takeover, but Merck stock was little moved on its EyeBio deal. 
Via Investor's Business Daily
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback